X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse IPCA Labs with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs ACTAVIS (US) - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 IPCA LABS   ACTAVIS
EQUITY SHARE DATA
    IPCA LABS
Mar-17
ACTAVIS
Dec-14
IPCA LABS/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs64317,402-   
Low Rs50310,615-   
Sales per share (Unadj.) Rs254.43,133.6-  
Earnings per share (Unadj.) Rs16.1-391.0-  
Cash flow per share (Unadj.) Rs29.8287.5-  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs194.66,796.7-  
Shares outstanding (eoy) m126.20265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.34.5 50.4%   
Avg P/E ratio x35.7-35.8 -99.5%  
P/CF ratio (eoy) x19.248.7 39.5%  
Price / Book Value ratio x2.92.1 142.9%  
Dividend payout %6.20-   
Avg Mkt Cap Rs m72,3003,724,803 1.9%   
No. of employees `00013.321.6 61.6%   
Total wages/salary Rs m6,9600-   
Avg. sales/employee Rs Th2,413.538,575.2 6.3%   
Avg. wages/employee Rs Th523.20-   
Avg. net profit/employee Rs Th152.4-4,813.8 -3.2%   
INCOME DATA
Net Sales Rs m32,106833,225 3.9%  
Other income Rs m226-2,080 -10.9%   
Total revenues Rs m32,332831,145 3.9%   
Gross profit Rs m4,448107,040 4.2%  
Depreciation Rs m1,730180,424 1.0%   
Interest Rs m24126,281 0.9%   
Profit before tax Rs m2,703-101,745 -2.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-7,463 0.0%   
Tax Rs m675-5,231 -12.9%   
Profit after tax Rs m2,028-103,978 -2.0%  
Gross profit margin %13.912.8 107.8%  
Effective tax rate %25.05.1 485.8%   
Net profit margin %6.3-12.5 -50.6%  
BALANCE SHEET DATA
Current assets Rs m17,340439,003 3.9%   
Current liabilities Rs m9,559320,162 3.0%   
Net working cap to sales %24.214.3 169.9%  
Current ratio x1.81.4 132.3%  
Inventory Days Days10058 172.9%  
Debtors Days Days5766 85.8%  
Net fixed assets Rs m20,779101,745 20.4%   
Share capital Rs m2520-   
"Free" reserves Rs m24,4990-   
Net worth Rs m24,5531,807,234 1.4%   
Long term debt Rs m3,517947,026 0.4%   
Total assets Rs m39,5953,312,066 1.2%  
Interest coverage x12.2-2.9 -425.8%   
Debt to equity ratio x0.10.5 27.3%  
Sales to assets ratio x0.80.3 322.3%   
Return on assets %5.7-2.3 -244.3%  
Return on equity %8.3-5.8 -143.6%  
Return on capital %10.5-3.0 -348.3%  
Exports to sales %48.60-   
Imports to sales %14.20-   
Net fx Rs m9,7900-   
CASH FLOW
From Operations Rs m2,764143,081 1.9%  
From Investments Rs m-1,432-342,591 0.4%  
From Financial Activity Rs m-1,591192,486 -0.8%  
Net Cashflow Rs m-259-7,023 3.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 63.79 Rs / USD

Compare IPCA LABS With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare IPCA LABS With: GLENMARK PHARMA  CIPLA  DR. DATSONS LABS  MERCK LTD  PIRAMAL ENTERPRISES  



Today's Market

Sensex Trades on a Volatile Note; Airtel, Idea Down by 5%(01:30 pm)

After opening the day in green share markets in India witnessed choppy trading activity and are presently trading above the dotted line.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jan 24, 2018 03:07 PM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS